Alkermes registers expanded access program for pediatric LYBALVI patients
Alkermes listed a new expanded access program letting pediatric patients continue OLZ/SAM after finishing a long-term safety study.
Alkermes had one registry item posted this week.
- OLZ/SAM (LYBALVI, ALKS 3831, olanzapine/samidorphan), expanded access, pediatric schizophrenia or bipolar I disorder: the program is meant to let pediatric patients keep receiving OLZ/SAM after finishing the ALKS 3831-A313 long-term safety extension study.1 The program is listed as available, with one site in Miami, Florida, and eligibility limited to patients ages 10 to 17 who have completed 52 weeks on the ALKS 3831-A313 clinical study.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.